University of Malaya
Kuala Lumpur, Jalan Pantai Baharu, 59990, Malaysia
NCT Number: NCT04910984
In this study, the feasibility of a Chatbot in promoting HIV testing in a pilot RCT with 80 men who have sex with men in Kuala Lumpur, Malaysia will be studied. Participants will be randomized to Chatbot or treatment as usual (TAU) groups. Participants in the intervention group will receive automated personalized messages containing HIV testing-related information, motivation and skills.
Trial opening soon.
Get Notified18 year and older
Male
Interventional
Not applicable
Kuala Lumpur, Jalan Pantai Baharu, 59990, Malaysia
After informed consent, participants will be randomly assigned to Chatbot or TAU groups using stratified randomization by age. Participants in TAU will receive attention-matched educational materials manually sent by the research assistant. Participants in the intervention group will receive an automated personalized question message (root-node message) from the Chabot. In each round of the interactive communication, the Chatbot will provide automated personalized messages containing HIV testing-related information, motivation and skills based on participants' answers and will continuously update over time. Participants will be observed over 180 days with responses and interactions stored on a HIPAA-compliant and protected cloud. An independent assessment of recent testing and reasons why will be sent by link to both TAU and intervention groups using a link to a Qualtrics survey housed on REDCap at baseline and after 90 and 180 days. After 180 days, the RA will send an additional REDCap survey to intervention participants to assess the feasibility of the Chabot to measure 4 key elements: acceptability, practicality, demand, and adaptation.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Automated personalized messages containing HIV testing-related information, motivation and skills
Attention-matched educational materials manually sent by our research assistant. These educational materials will be retrieved from CDC and WHO websites and curated into short articles (<200 words) and pictures. All educational materials will be screened by HIV experts from University of Malaya to ensure accuracy before being sent to participants.
Time frame: 30 days, 60 days, 90 days, 120 days, 150 days, and 180 days
The efficacy of the Chatbot versus TAU with HIV testing as the primary outcome will be measured. The primacy efficacy outcome is the proportion of MSM who get tested within 180 days. This will be measured every 30 days by asking if MSM tested for HIV in the past 30 days.
Time frame: 180 days
The number of participants contacted divided by the number of participants who signed the consent form
Time frame: 180 days
The number of participants who signed the consent form divided by the number of participants who completed the study
Time frame: 180 days
The time of the interaction between participants and Chatbot
Time frame: 180 days
The frequency of the interaction between participants and Chatbot
Yale University
Other
Developing an Artificial Intelligence Chatbot to Promote HIV Testing
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07516548
Blood-Borne Infections, Communicable Diseases
Bontleng, Gaborone, Botswana
View Trial DetailsNCT05771519
Blood-Borne Infections, Communicable Diseases
Mbarara, Uganda
View Trial DetailsNCT06068283
Blood-Borne Infections, Communicable Diseases
La Jolla, California, United States
View Trial DetailsNCT07597824
Blood-Borne Infections, Communicable Diseases
Bontleng, Gaborone, Botswana
View Trial Details